| pubmed-article:19404641 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19404641 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19404641 | lifeskim:mentions | umls-concept:C0750952 | lld:lifeskim |
| pubmed-article:19404641 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:19404641 | lifeskim:mentions | umls-concept:C1514474 | lld:lifeskim |
| pubmed-article:19404641 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19404641 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:19404641 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19404641 | pubmed:dateCreated | 2009-9-17 | lld:pubmed |
| pubmed-article:19404641 | pubmed:abstractText | The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy. | lld:pubmed |
| pubmed-article:19404641 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19404641 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19404641 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19404641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19404641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19404641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19404641 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19404641 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19404641 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:19404641 | pubmed:issn | 1432-0843 | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:FunakoshiAkih... | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:YamaguchiTake... | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:BokuNarikazuN | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:OkusakaTakuji... | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:YamaoKenjiK | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:OhkawaShinich... | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:FuruseJunjiJ | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:SatoToshiyaT | lld:pubmed |
| pubmed-article:19404641 | pubmed:author | pubmed-author:NagaseMichita... | lld:pubmed |
| pubmed-article:19404641 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19404641 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:19404641 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19404641 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19404641 | pubmed:pagination | 113-20 | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:meshHeading | pubmed-meshheading:19404641... | lld:pubmed |
| pubmed-article:19404641 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19404641 | pubmed:articleTitle | A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. | lld:pubmed |
| pubmed-article:19404641 | pubmed:affiliation | Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. jfuruse@ks.kyorin-u.ac.jp | lld:pubmed |
| pubmed-article:19404641 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19404641 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19404641 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
